1-20 of 43
Jos H. Beijnen
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in BRAFV600-Mutated Melanoma

Alaa Embaby, Sanne C.F.A. Huijberts, Liqin Wang, Rodrigo Leite de Oliveira, Hilde Rosing, Bastiaan Nuijen, Joyce Sanders, Ingrid Hofland, Charlaine van Steenis, Roelof J.C. Kluin, Cor Lieftink, Christopher G. Smith, Christian U. Blank, Johannes V. van Thienen, John B.A.G. Haanen, Neeltje Steeghs, Frans L. Opdam, Jos H. Beijnen, Alwin D.R. Huitema, Rene Bernards, Jan H.M. Schellens, Sofie Wilgenhof
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (15): 3157–3166.
https://doi.org/10.1158/1078-0432.CCR-23-3171
Published: 01 August 2024
View article titled, A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in <em>BRAF</em><sup><em>V600</em></sup>-Mutated Melanoma
Open the PDF for A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in <em>BRAF</em><sup><em>V600</em></sup>-Mutated Melanoma in another window
Includes: Supplementary data
Journal Articles

Precision Dosing of Targeted Therapies Is Ready for Prime Time

Stefanie L. Groenland, Remy B. Verheijen, Markus Joerger, Ron H.J. Mathijssen, Alex Sparreboom, Jos H. Beijnen, Jan H. Beumer, Neeltje Steeghs, Alwin D.R. Huitema
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (24): 6644–6652.
https://doi.org/10.1158/1078-0432.CCR-20-4555
Published: 15 December 2021
View article titled, Precision Dosing of Targeted Therapies Is Ready for Prime Time
Open the PDF for Precision Dosing of Targeted Therapies Is Ready for Prime Time in another window
Journal Articles

A Phase I Dose Escalation Study of Once-Weekly Oral Administration of Docetaxel as ModraDoc001 Capsule or ModraDoc006 Tablet in Combination with Ritonavir

Vincent A. de Weger, Frederik E. Stuurman, Stijn L.W. Koolen, Johannes J. Moes, Jeroen J.M.A. Hendrikx, Emilia Sawicki, Bas Thijssen, Marianne Keessen, Hilde Rosing, Marja Mergui-Roelvink, Alwin D.R. Huitema, Bastiaan Nuijen, Jos H. Beijnen, Jan H.M. Schellens, Serena Marchetti
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (18): 5466–5474.
https://doi.org/10.1158/1078-0432.CCR-17-2299
Published: 13 September 2019
View article titled, A Phase I Dose Escalation Study of Once-Weekly Oral Administration of Docetaxel as ModraDoc001 Capsule or ModraDoc006 Tablet in Combination with Ritonavir
Open the PDF for A Phase I Dose Escalation Study of Once-Weekly Oral Administration of Docetaxel as ModraDoc001 Capsule or ModraDoc006 Tablet in Combination with Ritonavir in another window
Journal Articles

PI3K–mTOR Pathway Inhibition Exhibits Efficacy Against High-grade Glioma in Clinically Relevant Mouse Models

Fan Lin, Mark C. de Gooijer, Diana Hanekamp, Gayathri Chandrasekaran, Levi C.M. Buil, Nishita Thota, Rolf W. Sparidans, Jos H. Beijnen, Tom Würdinger, Olaf van Tellingen
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (5): 1286–1298.
https://doi.org/10.1158/1078-0432.CCR-16-1276
Published: 28 February 2017
View article titled, PI3K–mTOR Pathway Inhibition Exhibits Efficacy Against High-grade Glioma in Clinically Relevant Mouse Models
Open the PDF for PI3K–mTOR Pathway Inhibition Exhibits Efficacy Against High-grade Glioma in Clinically Relevant Mouse Models in another window
Includes: Supplementary data
Journal Articles

Individualized Pazopanib Dosing: A Prospective Feasibility Study in Cancer Patients

Remy B. Verheijen, Sander Bins, Ron H.J. Mathijssen, Martijn P. Lolkema, Leni van Doorn, Jan H.M. Schellens, Jos H. Beijnen, Marlies H.G. Langenberg, Alwin D.R. Huitema, Neeltje Steeghs
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (23): 5738–5746.
https://doi.org/10.1158/1078-0432.CCR-16-1255
Published: 30 November 2016
View article titled, Individualized Pazopanib Dosing: A Prospective Feasibility Study in Cancer Patients
Open the PDF for Individualized Pazopanib Dosing: A Prospective Feasibility Study in Cancer Patients in another window
Journal Articles

P-Glycoprotein, CYP3A, and Plasma Carboxylesterase Determine Brain and Blood Disposition of the mTOR Inhibitor Everolimus (Afinitor) in Mice

Seng Chuan Tang, Rolf W. Sparidans, Ka Lei Cheung, Tatsuki Fukami, Selvi Durmus, Els Wagenaar, Tsuyoshi Yokoi, Bart J.M. van Vlijmen, Jos H. Beijnen, Alfred H. Schinkel
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (12): 3133–3145.
https://doi.org/10.1158/1078-0432.CCR-13-1759
Published: 12 June 2014
View article titled, P-Glycoprotein, CYP3A, and Plasma Carboxylesterase Determine Brain and Blood Disposition of the mTOR Inhibitor Everolimus (Afinitor) in Mice
Open the PDF for P-Glycoprotein, CYP3A, and Plasma Carboxylesterase Determine Brain and Blood Disposition of the mTOR Inhibitor Everolimus (Afinitor) in Mice in another window
Includes: Supplementary data
Journal Articles

ABCB1, ABCG2, and PTEN Determine the Response of Glioblastoma to Temozolomide and ABT-888 Therapy

Fan Lin, Mark C. de Gooijer, Eloy Moreno Roig, Levi C.M. Buil, Susan M. Christner, Jan H. Beumer, Thomas Würdinger, Jos H. Beijnen, Olaf van Tellingen
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (10): 2703–2713.
https://doi.org/10.1158/1078-0432.CCR-14-0084
Published: 14 May 2014
View article titled, ABCB1, ABCG2, and PTEN Determine the Response of Glioblastoma to Temozolomide and ABT-888 Therapy
Open the PDF for ABCB1, ABCG2, and PTEN Determine the Response of Glioblastoma to Temozolomide and ABT-888 Therapy in another window
Includes: Supplementary data
Journal Articles

Abcc4 Together with Abcb1 and Abcg2 Form a Robust Cooperative Drug Efflux System That Restricts the Brain Entry of Camptothecin Analogues

Fan Lin, Serena Marchetti, Dick Pluim, Dilek Iusuf, Roberto Mazzanti, Jan H.M. Schellens, Jos H. Beijnen, Olaf van Tellingen
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (8): 2084–2095.
https://doi.org/10.1158/1078-0432.CCR-12-3105
Published: 15 April 2013
View article titled, Abcc4 Together with Abcb1 and Abcg2 Form a Robust Cooperative Drug Efflux System That Restricts the Brain Entry of Camptothecin Analogues
Open the PDF for Abcc4 Together with Abcb1 and Abcg2 Form a Robust Cooperative Drug Efflux System That Restricts the Brain Entry of Camptothecin Analogues in another window
Journal Articles

Phase I Study of Oral Gemcitabine Prodrug (LY2334737) Alone and in Combination with Erlotinib in Patients with Advanced Solid Tumors

Stijn L.W. Koolen, Petronella O. Witteveen, Robert S. Jansen, Marlies H.G. Langenberg, Roelien H. Kronemeijer, Annemarie Nol, Ignacio Garcia-Ribas, Sophie Callies, Karim A. Benhadji, Christopher A. Slapak, Jos H. Beijnen, Emile E. Voest, Jan H.M. Schellens
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (18): 6071–6082.
https://doi.org/10.1158/1078-0432.CCR-11-0353
Published: 14 September 2011
View article titled, Phase I Study of Oral Gemcitabine Prodrug (LY2334737) Alone and in Combination with Erlotinib in Patients with Advanced Solid Tumors
Open the PDF for Phase I Study of Oral Gemcitabine Prodrug (LY2334737) Alone and in Combination with Erlotinib in Patients with Advanced Solid Tumors in another window
Journal Articles

Relationship between Single Nucleotide Polymorphisms and Haplotypes in DPYD and Toxicity and Efficacy of Capecitabine in Advanced Colorectal Cancer

Maarten J. Deenen, Jolien Tol, Artur M Burylo, Valerie D. Doodeman, Anthonius de Boer, Andrew Vincent, Henk-Jan Guchelaar, Paul H.M. Smits, Jos H. Beijnen, Cornelis J.A. Punt, Jan H.M. Schellens, Annemieke Cats
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (10): 3455–3468.
https://doi.org/10.1158/1078-0432.CCR-10-2209
Published: 15 May 2011
View article titled, Relationship between Single Nucleotide Polymorphisms and Haplotypes in <em>DPYD</em> and Toxicity and Efficacy of Capecitabine in Advanced Colorectal Cancer
Open the PDF for Relationship between Single Nucleotide Polymorphisms and Haplotypes in <em>DPYD</em> and Toxicity and Efficacy of Capecitabine in Advanced Colorectal Cancer in another window
Includes: Supplementary data
Journal Articles

Rapid and Robust Transgenic High-Grade Glioma Mouse Models for Therapy Intervention Studies

Nienke A. de Vries, Sophia W. Bruggeman, Danielle Hulsman, Hilda I. de Vries, John Zevenhoven, Tessa Buckle, Bob C. Hamans, William P. Leenders, Jos H. Beijnen, Maarten van Lohuizen, Anton J.M. Berns, Olaf van Tellingen
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (13): 3431–3441.
https://doi.org/10.1158/1078-0432.CCR-09-3414
Published: 01 July 2010
View article titled, Rapid and Robust Transgenic High-Grade Glioma Mouse Models for Therapy Intervention Studies
Open the PDF for Rapid and Robust Transgenic High-Grade Glioma Mouse Models for Therapy Intervention Studies in another window
Includes: Supplementary data
Journal Articles

P-glycoprotein (P-gp/Abcb1), Abcc2, and Abcc3 Determine the Pharmacokinetics of Etoposide

Jurjen S. Lagas, Lin Fan, Els Wagenaar, Maria L.H. Vlaming, Olaf van Tellingen, Jos H. Beijnen, Alfred H. Schinkel
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (1): 130–140.
https://doi.org/10.1158/1078-0432.CCR-09-1321
Published: 04 January 2010
View article titled, P-glycoprotein (P-gp/Abcb1), Abcc2, and Abcc3 Determine the Pharmacokinetics of Etoposide
Open the PDF for P-glycoprotein (P-gp/Abcb1), Abcc2, and Abcc3 Determine the Pharmacokinetics of Etoposide in another window
Includes: Supplementary data
Journal Articles

ABCC2, ABCC3, and ABCB1, but not CYP3A, Protect against Trabectedin-Mediated Hepatotoxicity

Robert A.B. van Waterschoot, Rhandy M. Eman, Els Wagenaar, Cornelia M.M. van der Kruijssen, Hilde Rosing, Jos H. Beijnen, Alfred H. Schinkel
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (24): 7616–7623.
https://doi.org/10.1158/1078-0432.CCR-09-2127
Published: 14 December 2009
View article titled, ABCC2, ABCC3, and ABCB1, but not CYP3A, Protect against Trabectedin-Mediated Hepatotoxicity
Open the PDF for ABCC2, ABCC3, and ABCB1, but not CYP3A, Protect against Trabectedin-Mediated Hepatotoxicity in another window
Includes: Supplementary data
Journal Articles

Phase I Pharmacokinetic and Pharmacodynamic Study of Carboplatin and Topotecan Administered Intravenously Every 28 Days to Patients with Malignant Solid Tumors

David S. Boss, Wandena S. Siegel-Lakhai, Nadja E. van Egmond-Schoemaker, Dick Pluim, Hilde Rosing, Wim W. ten Bokkel Huinink, Jos H. Beijnen, Jan H.M. Schellens
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (13): 4475–4483.
https://doi.org/10.1158/1078-0432.CCR-08-3144
Published: 01 July 2009
View article titled, Phase I Pharmacokinetic and Pharmacodynamic Study of Carboplatin and Topotecan Administered Intravenously Every 28 Days to Patients with Malignant Solid Tumors
Open the PDF for Phase I Pharmacokinetic and Pharmacodynamic Study of Carboplatin and Topotecan Administered Intravenously Every 28 Days to Patients with Malignant Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Coadministration of Ritonavir Strongly Enhances the Apparent Oral Bioavailability of Docetaxel in Patients with Solid Tumors

Roos L. Oostendorp, Alwin Huitema, Hilde Rosing, Robert S. Jansen, Rob ter Heine, Marianne Keessen, Jos H. Beijnen, Jan H.M. Schellens
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (12): 4228–4233.
https://doi.org/10.1158/1078-0432.CCR-08-2944
Published: 15 June 2009
View article titled, Coadministration of Ritonavir Strongly Enhances the Apparent Oral Bioavailability of Docetaxel in Patients with Solid Tumors
Open the PDF for Coadministration of Ritonavir Strongly Enhances the Apparent Oral Bioavailability of Docetaxel in Patients with Solid Tumors in another window
Journal Articles

Brain Accumulation of Dasatinib Is Restricted by P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) and Can Be Enhanced by Elacridar Treatment

Jurjen S. Lagas, Robert A.B. van Waterschoot, Vicky A.C.J. van Tilburg, Michel J. Hillebrand, Nienke Lankheet, Hilde Rosing, Jos H. Beijnen, Alfred H. Schinkel
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (7): 2344–2351.
https://doi.org/10.1158/1078-0432.CCR-08-2253
Published: 01 April 2009
View article titled, Brain Accumulation of Dasatinib Is Restricted by P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) and Can Be Enhanced by Elacridar Treatment
Open the PDF for Brain Accumulation of Dasatinib Is Restricted by P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) and Can Be Enhanced by Elacridar Treatment in another window
Journal Articles

Clinical and Pharmacologic Study of the Novel Prodrug Delimotecan (MEN 4901/T-0128) in Patients with Solid Tumors

Stephan A. Veltkamp, Els O. Witteveen, Angela Capriati, Attilio Crea, Fabio Animati, Marja Voogel-Fuchs, Ingeborg J.G.M. van den Heuvel, Jos H. Beijnen, Emile E. Voest, Jan H.M. Schellens
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (22): 7535–7544.
https://doi.org/10.1158/1078-0432.CCR-08-0438
Published: 14 November 2008
View article titled, Clinical and Pharmacologic Study of the Novel Prodrug Delimotecan (MEN 4901/T-0128) in Patients with Solid Tumors
Open the PDF for Clinical and Pharmacologic Study of the Novel Prodrug Delimotecan (MEN 4901/T-0128) in Patients with Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Oral Administration of Gemcitabine in Patients with Refractory Tumors: A Clinical and Pharmacologic Study

Stephan A. Veltkamp, Robert S. Jansen, Sophie Callies, Dick Pluim, Carla M. Visseren-Grul, Hilde Rosing, Susanne Kloeker-Rhoades, Valerie A.M. Andre, Jos H. Beijnen, Christopher A. Slapak, Jan H.M. Schellens
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (11): 3477–3486.
https://doi.org/10.1158/1078-0432.CCR-07-4521
Published: 02 June 2008
View article titled, Oral Administration of Gemcitabine in Patients with Refractory Tumors: A Clinical and Pharmacologic Study
Open the PDF for Oral Administration of Gemcitabine in Patients with Refractory Tumors: A Clinical and Pharmacologic Study in another window
Journal Articles

P-Glycoprotein and Breast Cancer Resistance Protein: Two Dominant Transporters Working Together in Limiting the Brain Penetration of Topotecan

Nienke A. de Vries, Jin Zhao, Emily Kroon, Tessa Buckle, Jos H. Beijnen, Olaf van Tellingen
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (21): 6440–6449.
https://doi.org/10.1158/1078-0432.CCR-07-1335
Published: 01 November 2007
View article titled, P-Glycoprotein and Breast Cancer Resistance Protein: Two Dominant Transporters Working Together in Limiting the Brain Penetration of Topotecan
Open the PDF for P-Glycoprotein and Breast Cancer Resistance Protein: Two Dominant Transporters Working Together in Limiting the Brain Penetration of Topotecan in another window
Journal Articles

Population Pharmacokinetics and Pharmacodynamics of Paclitaxel and Carboplatin in Ovarian Cancer Patients: A Study by the European Organization for Research and Treatment of Cancer-Pharmacology and Molecular Mechanisms Group and New Drug Development Group

Markus Joerger, Alwin D.R. Huitema, Dick J. Richel, Christian Dittrich, Nikolas Pavlidis, Evangelos Briasoulis, Jan B. Vermorken, Elena Strocchi, Andrea Martoni, Roberto Sorio, Henk P. Sleeboom, Miguel A. Izquierdo, Duncan I. Jodrell, Hilary Calvert, Alan V. Boddy, Harry Hollema, Regine Féty, Wjf J.F. Van der Vijgh, Georg Hempel, Etienne Chatelut, Mats Karlsson, Justin Wilkins, Brigitte Tranchand, Ad H.G.J. Schrijvers, Christian Twelves, Jos H. Beijnen, Jan H.M. Schellens
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (21): 6410–6418.
https://doi.org/10.1158/1078-0432.CCR-07-0064
Published: 01 November 2007
View article titled, Population Pharmacokinetics and Pharmacodynamics of Paclitaxel and Carboplatin in Ovarian Cancer Patients: A Study by the European Organization for Research and Treatment of Cancer-Pharmacology and Molecular Mechanisms Group and New Drug Development Group
Open the PDF for Population Pharmacokinetics and Pharmacodynamics of Paclitaxel and Carboplatin in Ovarian Cancer Patients: A Study by the European Organization for Research and Treatment of Cancer-Pharmacology and Molecular Mechanisms Group and New Drug Development Group in another window